JAKAVI demonstrated overall survival benefit in patients with MF1
At 3.5-year follow-up, patients randomized to JAKAVI arm had improved overall survival compared with patients treated with BAT1
COMFORT-II: Overall survival at 3.5-year follow-up of JAKAVI vs BAT1

Adapted from: Harrison C et al. Abstract presented at: 19th Congress of European Hematology Association, 2014.1
Of the 73 patients originally randomised to BAT, 45 (62%) crossed over to JAKAVI after a median duration of 66 weeks.
In the ITT analysis of overall survival, patients who crossed over from the BAT arm to receive JAKAVI were included in the BAT group.1
- At 1-year follow-up (median: 61.1 weeks) in COMFORT-II, survival improvement was not yet evident2
- At an unplanned 2-year analysis (median: 112 weeks), a survival trend emerged in favor of JAKAVI (HR: 0.52; 95% CI: 0.27-0.99; P=0.041)2
- At 3.5-year follow-up, the probability of survival was 71% in the JAKAVI arm and 54% in the BAT arm (HR=0.58; 95% CI: 0.36-0.93; P=0.02)1
JAKAVI improved overall survival compared with placebo at 3-year follow-up3
- At 1-year follow-up (median: 52 and 51 weeks), JAKAVI demonstrated survival improvement (HR=0.50; 95% CI: 0.25-0.98; P=0.04)2
- At 2-year follow-up (median: 102 weeks), JAKAVI demonstrated improved overall survival compared with placebo (HR=0.58; 95% CI: 0.36-0.95; P=0.028)2
- At 3-year follow-up (median: 149 weeks), JAKAVI improved overall survival compared with placebo (HR=0.69; 95% CI: 0.46-1.03; P=0.067)3